RE: Successful in an Azactidine refractory patient5 Dec 2022 17:30
So the question is who owns azacitidine and venetoclax?
And at what point do they say, we need Bex as a standard treatment alongside our treatments to have 100% survival rates?
And would they buy us out? Or partner to get bex fully to market.
Just a quick look online we may be looking at Abbvie and Pfizer?